LILRB2 | Jotup

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

Retrieved on:

Monday, April 8, 2024

B cell, Ligand, Patient, CHRS, Tumor microenvironment, LILRB2, Cancer, Macrophage, PD-1, Neonatal Fc receptor, IND, Phenotype, Neoplasm, Poster, ILT4, Vaccine

REDWOOD CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today presented preclinical data for its immuno-oncology pipeline candidate, CHS-1000, a novel ILT4 monoclonal antibody, at the 2024 AACR Annual Meeting being held in San Diego, California. Data presented show CHS-1000 is a potent monoclonal antibody that binds selectively to human ILT4 (also known as LILRB2) with high affinity, efficiently blocking interaction with its ligands and reversing immunosuppressive functions, leading to activation of human dendritic cells and T cells and promoting polarization of macrophages to an inflammatory M1 phenotype.

Key Points:

“Myeloid cell-mediated immunosuppression in the tumor microenvironment is a major contributor to tumor immune invasion and PD-1 resistance.
The data presented in this poster demonstrate the potential for CHS-1000 to reverse myeloid suppression and activate an inflammatory immune response.
“CHS-1000 is our first internally discovered development candidate, and we are excited to be filing the IND this quarter.
ILT4 and CD163, a marker of suppressive (M2) macrophages, are highly expressed in a broad range of solid tumors.

Immune-Onc Therapeutics Announces Clinical Trial Collaboration to Evaluate IO-108 in a Randomized Global Phase 1b/2 Study for First-Line Treatment of Advanced Liver Cancer

Retrieved on:

Tuesday, February 20, 2024

Atezolizumab and bevacizumab is the first cancer immunotherapy combination regimen approved by the U.S. Food and Drug Administration for this setting and is the recommended standard of care by the National Comprehensive Cancer Network.

Key Points:

Atezolizumab and bevacizumab is the first cancer immunotherapy combination regimen approved by the U.S. Food and Drug Administration for this setting and is the recommended standard of care by the National Comprehensive Cancer Network.
“We are excited to work with Roche to accelerate the development of IO-108,” said Charlene Liao, Ph.D., chief executive officer and board chair of Immune-Onc.
“IO-108 has demonstrated clinical activity and an acceptable safety profile across multiple solid tumors as monotherapy and in combination with T cell checkpoint inhibitors.
The collaboration marks a significant milestone in establishing IO-108 as the preferred myeloid checkpoint inhibitor for combination with standard of care immunotherapy regimens in solid tumors.”
Under the collaboration, Roche will sponsor and conduct the global, randomized Phase 1b/2 trial to evaluate the safety, efficacy and pharmacodynamics of IO-108 in combination with atezolizumab and bevacizumab compared to atezolizumab and bevacizumab, the standard of care treatment regimen for advanced liver cancer.

ImmunOs Therapeutics Presents Details of Novel Bispecific Anti-Tumor Molecules at ESMO Immuno-Oncology Congress 2023

Retrieved on:

Monday, December 11, 2023

ESMO, Neoplasm, Immune system, LILRB2, CD47, HLA, Alpha globulin, Doctor of Philosophy, Therapy, KIR3DL1, CDO, Cancer, Inflammation, Myelocyte, CSO, Patient, LILRB1

Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – December 11, 2023 – ImmunOs Therapeutics AG , a biopharmaceutical company pioneering HLA-based therapeutics to create transformational medicines for cancer and inflammation, announced details of its novel multi-functional anti-cancer modality at ESMO Immuno-Oncology Congress 2023 in Geneva (Switzerland) on December 7, 2023.

Key Points:

Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – December 11, 2023 – ImmunOs Therapeutics AG , a biopharmaceutical company pioneering HLA-based therapeutics to create transformational medicines for cancer and inflammation, announced details of its novel multi-functional anti-cancer modality at ESMO Immuno-Oncology Congress 2023 in Geneva (Switzerland) on December 7, 2023.
“We already have encouraging in vitro data demonstrating potent anti-tumor efficacy and primary cell data demonstrating an enhanced safety profile compared to competing CD47 targeting molecules,” said Osiris Marroquin Belaunzaran, PhD, CSO and co-founder of ImmunOs Therapeutics.
“We believe that HLA molecules can serve as a versatile backbone to develop novel therapies capable of stimulating the immune system of cancer patients to eliminate tumor cells.
Moreover, we are also utilizing specific HLA molecules to develop novel therapies to treat inflammatory diseases.”

SparX Biopharmaceutical Announces FDA Greenlight for IND Application of SPX-303, A First-In-Human anti-LILRB2/PD-L1 Antibody Drug

Retrieved on:

Monday, October 30, 2023

FDA, PD-L1, Trial of the century, Sparx, IND, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Biopharmaceutical, LILRB2, Neoplasm, Immune system, Cancer, Safety, Patient, Pharmaceutical industry, Vaccine

CHICAGO, Oct. 30, 2023 /PRNewswire/ -- Signifying a monumental step forward in the domain of powered antibody therapies, SparX Biopharmaceutical Corp. proudly announces that its Investigational New Drug (IND) application for SPX-303, a First-in-Class anti-LILRB2/PD-L1 bispecific antibody drug candidate, has been greenlighted by the U.S. Food and Drug Administration (FDA).

Key Points:

CHICAGO, Oct. 30, 2023 /PRNewswire/ -- Signifying a monumental step forward in the domain of powered antibody therapies, SparX Biopharmaceutical Corp. proudly announces that its Investigational New Drug (IND) application for SPX-303, a First-in-Class anti-LILRB2/PD-L1 bispecific antibody drug candidate, has been greenlighted by the U.S. Food and Drug Administration (FDA).
This approval propels SparX's enduring commitment to deliver groundbreaking solutions to patients grappling with advanced or refractory solid tumors.
Dr. Gui-Dong Zhu, Chief Executive Officer of SparX Biopharmaceutical, shared his exhilaration: "Receiving the FDA's green light on our IND application is a seminal moment in our ongoing journey to redefine the paradigms of cancer treatment.
Developed by SparX, SPX-303 is a First-in-Its Class bispecific antibody therapy, ingeniously engineered to engage two cardinal immune checkpoint proteins, LILRB2 and PD-L1, simultaneously.

ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002

Retrieved on:

Tuesday, October 24, 2023

The update was presented at ESMO Congress 2023 in Madrid (Spain) on October 23, 2023.

Key Points:

The update was presented at ESMO Congress 2023 in Madrid (Spain) on October 23, 2023.
A second cohort of IOS-1002 in combination with pembrolizumab will be initiated after completion of the fifth dose level.
The Phase 1a/b trial is expected to enroll over 120 patients.
"We are pleased that the trial is progressing as planned," said Christoph Renner, M.D., CMO and co-founder of ImmunOs Therapeutics.

ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA

Retrieved on:

Tuesday, October 17, 2023

LILRB1, Merck Sharp & Dohme Federal Credit Union, Immuno-psychiatry, Pembrolizumab, Inflammation, Therapy, Merck & Co., Safety, ILT4, Cancer, LILRB2, Merck, HLA, KIR3DL1, ILT2, Patient, Pharmaceutical industry, MD

IOS-1002 is a first-in-class checkpoint inhibitor targeting LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1.

Key Points:

IOS-1002 is a first-in-class checkpoint inhibitor targeting LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1.
ImmunOs is currently enrolling patients in the Phase 1a/b trial, initiated earlier this year, to evaluate the potential of IOS-1002 as a monotherapy and in combination with KEYTRUDA in adult patients with advanced solid tumors.
“We are pleased to enter into this agreement for our ongoing Phase 1a/b trial of IOS-1002,” said Christoph Renner, M.D., Chief Medical Officer, and co-founder of ImmunOs.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Elpiscience Announces First Patient Dosed for Phase 1 Clinical Trial of Anti-LILRB2 Antibody ES009 in Australia

Retrieved on:

Tuesday, September 26, 2023

Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Myelocyte, Cancer, Pharmacokinetics, ILT4, Therapy, CSO, Tumor microenvironment, Phenotype, Patient, Biopharmaceutical, LILRB2, Safety, TME, Vaccine

Elpiscience Biopharmaceuticals (“Elpiscience”), a clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation cancer immunotherapies, announced today that the first patient has been dosed in a Phase 1 clinical trial of its anti-LILRB2 monoclonal antibody ES009 in Australia.

Key Points:

Elpiscience Biopharmaceuticals (“Elpiscience”), a clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation cancer immunotherapies, announced today that the first patient has been dosed in a Phase 1 clinical trial of its anti-LILRB2 monoclonal antibody ES009 in Australia.
The objective of the trial is to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity.
ES009 specifically binds to a unique epitope on human LILRB2 and potently blocks LILRB2 binding to multiple ligands.
By blocking LILRB2-mediated inhibitory signaling, ES009 can reprogram myeloid cells from anti-inflammatory phenotype into pro-inflammatory phenotype, and reinvigorate T cell functionalities.

ImmunOs Therapeutics Announces Initiation of Dosing in Phase 1 Trial of Lead Compound IOS-1002

Retrieved on:

Wednesday, May 24, 2023

LILRB1, ILT2, University, Therapy, LILRB2, HLA, University of Melbourne, Cancer, Pharmacokinetics, Immuno-psychiatry, ILT4, Patient, Immune system, Peter MacCallum Cancer Centre, Trial of the century, KIR3DL1, Safety, Vaccine, Pharmaceutical industry

Schlieren (Zurich Area), Switzerland – May 24, 2023 – ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the initiation of dosing of patients in a Phase 1 trial of its lead program IOS-1002 in Australia.

Key Points:

Schlieren (Zurich Area), Switzerland – May 24, 2023 – ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the initiation of dosing of patients in a Phase 1 trial of its lead program IOS-1002 in Australia.
IOS-1002 is a first-in-class checkpoint inhibitor targeting LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1 for the treatment of advanced solid tumors.
Primary endpoints of the current Phase 1a, first-in-human, open-label, non-randomized, multicenter study will be the safety and tolerability of IOS-1002.
"We are excited that our lead compound IOS-1002 has entered into a first-in-human trial and that patients are being dosed," said Sean R. Smith, CEO of ImmunOs Therapeutics.

OncoResponse Presents at AACR 2023 Annual Meeting Preclinical Data Highlighting Dual Antagonist Antibodies Targeting both LILRB1 and LILRB2

Retrieved on:

Wednesday, April 19, 2023

LILRB1, Immunosuppression, LILRB2, Tumor microenvironment, Antibody, Doctor of Philosophy, Vaccine

SEATTLE, April 19, 2023 /PRNewswire/ -- OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders, today presented preclinical data highlighting its identification of dual antagonist antibodies targeting both LILRB1 and LILRB2 as potential anti-cancer immunotherapies at the American Association for Cancer Research Annual Meeting in Orlando, Florida.

Key Points:

SEATTLE, April 19, 2023 /PRNewswire/ -- OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders, today presented preclinical data highlighting its identification of dual antagonist antibodies targeting both LILRB1 and LILRB2 as potential anti-cancer immunotherapies at the American Association for Cancer Research Annual Meeting in Orlando, Florida.
"We are excited about the potential of dual antagonist antibodies targeting LILRB1 and LILRB2, as our preclinical research provides compelling evidence of their ability to generate anti-tumor responses.
These results support further development of lead anti-LILRB2/1 antibodies, as well as our OR502 anti-LILRB2 clinical candidate, as new approaches for cancer immunotherapy."
The presentation highlighted the discovery and characterization of dual antagonist antibodies that target both LILRB1 and LILRB2, inhibitory receptors that promote immunosuppression within the tumor microenvironment.

Immune-Onc Therapeutics to Present Encouraging Phase 1 Data for IO-108 at AACR Annual Meeting 2023

Retrieved on:

Friday, April 14, 2023

The data will be presented in an oral session at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida, April 18.

Key Points:

The data will be presented in an oral session at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida, April 18.
Preclinical data for IO-312, a novel bispecific antibody targeting LILRB4 (ILT3) and CD3 (LILRB4 x CD3) will also be presented on April 18 as a late-breaking poster at AACR 2023.
Treatment with IO-108 was well-tolerated to the maximum administered dose (1800 mg Q3W); the maximum tolerated dose was not reached.
These findings suggest that LILRB2 is a critically important immunotherapy target.”
The initial data from dose escalation supports further development of IO-108.